As per the agreement, Ranbaxy will pay royalties on net sales of Absorica to Cipher.
Ranbaxy Americas senior vice president and regional director Venkat Krishnan said, "Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy’s specialized dermatology sales force."
Cipher president and CEO Larry Andrews said the company looks forward to work with Ranbaxy Laboratories in preparation for the upcoming US launch of the product through its dermatology sales force.
Absorica is a novel, patented brand formulation of the acne medication isotretinoin, developed by Cipher, for the treatment of severe recalcitrant nodular acne.